AAAAAA
Results:
1-19
|
Results: 19
Authors:
Osoba, D
Northfelt, DW
Budd, DW
Himmelberger, D
Citation: D. Osoba et al., Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine, CANCER INV, 19(6), 2001, pp. 573-580
Authors:
Zee, BC
Osoba, D
Citation: Bc. Zee et D. Osoba, Health-related quality-of-life outcomes, HANDBOOK OF STATISTICS IN CLINICAL ONCOLOGY, 2001, pp. 249-267
Authors:
Osoba, D
Brada, M
Prados, MD
Yung, WKA
Citation: D. Osoba et al., Effect of disease burden on health-related quality of life in patients with malignant gliomas, NEURO-ONCOL, 2(4), 2000, pp. 221-228
Authors:
Revicki, DA
Osoba, D
Fairclough, D
Barofsky, I
Berzon, R
Leidy, NK
Rothman, M
Citation: Da. Revicki et al., Recommendations on health-related quality of life research to support labeling and promotional claims in the United States, QUAL LIFE R, 9(8), 2000, pp. 887-900
Authors:
Osoba, D
Brada, M
Yung, WKA
Prados, MD
Citation: D. Osoba et al., Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide, EUR J CANC, 36(14), 2000, pp. 1788-1795
Authors:
Osoba, D
Citation: D. Osoba, Health-related quality-of-life assessment in clinical trials of supportivecare in oncology, SUPP CARE C, 8(2), 2000, pp. 84-88
Authors:
Osoba, D
Brada, M
Yung, WKA
Prados, M
Citation: D. Osoba et al., Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme, J CL ONCOL, 18(7), 2000, pp. 1481-1491
Authors:
Norris, B
Pritchard, KI
James, K
Myles, J
Bennett, K
Marlin, S
Skillings, J
Findlay, B
Vandenberg, T
Goss, P
Latreille, J
Rudinskas, L
Lofters, W
Trudeau, M
Osoba, D
Rodgers, A
Citation: B. Norris et al., Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8, J CL ONCOL, 18(12), 2000, pp. 2385-2394
Authors:
Osoba, D
Citation: D. Osoba, Effects of temozolomide in malignant brain tumours, LANCET, 356(9226), 2000, pp. 342-342
Authors:
Yung, WKA
Albright, RE
Olson, J
Fredericks, R
Fink, K
Prados, MD
Brada, M
Spence, A
Hohl, RJ
Shapiro, W
Glantz, M
Greenberg, H
Selker, RG
Vick, NA
Rampling, R
Friedman, H
Phillips, P
Bruner, J
Yue, N
Osoba, D
Zaknoen, S
Levin, VA
Citation: Wka. Yung et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, BR J CANC, 83(5), 2000, pp. 588-593
Authors:
Epstein, JB
Emerton, S
Kolbinson, DA
Le, ND
Phillips, N
Stevenson-Moore, P
Osoba, D
Citation: Jb. Epstein et al., Quality of life and oral function following radiotherapy for head and neckcancer, HEAD NECK, 21(1), 1999, pp. 1-11
Authors:
Osoba, D
Citation: D. Osoba, What has been learned from measuring health-related quality of life in clinical oncology, EUR J CANC, 35(11), 1999, pp. 1565-1570
Authors:
Stockler, MR
Osoba, D
Corey, P
Goodwin, PJ
Tannock, IF
Citation: Mr. Stockler et al., Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module, J CLIN EPID, 52(7), 1999, pp. 653-666
Authors:
Gralla, RJ
Osoba, D
Kris, MG
Kirkbride, P
Hesketh, PJ
Chinnery, LW
Clark-Snow, R
Gill, DP
Groshen, S
Grunberg, S
Koeller, JM
Morrow, GR
Perez, EA
Silber, JH
Pfister, DG
Citation: Rj. Gralla et al., Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines, J CL ONCOL, 17(9), 1999, pp. 2971-2994
Authors:
Murray, N
Livingston, RB
Shepherd, FA
James, K
Zee, B
Langleben, A
Kraut, M
Bearden, J
Goodwin, JW
Grafton, C
Turrisi, A
Walde, D
Croft, H
Osoba, D
Ottaway, J
Gandara, D
Citation: N. Murray et al., Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group, J CL ONCOL, 17(8), 1999, pp. 2300-2308
Authors:
Osoba, D
Tannock, I
Citation: D. Osoba et I. Tannock, Measuring health-related quality of life, J CL ONCOL, 17(7), 1999, pp. 2293-2293
Authors:
Osoba, D
Tannock, IF
Ernst, DS
Neville, AJ
Citation: D. Osoba et al., Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone, J CL ONCOL, 17(6), 1999, pp. 1654-1663
Authors:
Osoba, D
Burchmore, M
Citation: D. Osoba et M. Burchmore, Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin), SEMIN ONCOL, 26(4), 1999, pp. 84-88
Authors:
Osoba, D
Citation: D. Osoba, Interpreting the meaningfulness of changes in health-related quality of life scores: Lessons from studies in adults, INT J CANC, 1999, pp. 132-137
Risultati:
1-19
|